AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
BioAdaptives Inc.
Video analysis: BDPT
All videosNo video analysis for this stock yet. Request one from our team.
News: BDPT
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
Initial XcellaraHeart™ orders ship next week, marking the commercial launch of the Xcellara™ cellular wellness platform; Company prepares XcellaraResilience™ for October launch and highlights the retirement of major convertible debt and 43.25M insider shares. LAS VEGAS, NV / ACCESS Newswire / September 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of science-driven human renewal formulations, today announced that the first commercial orders for XcellaraHeart™ will ship next week.
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
Former UFC middleweight champion and current broadcaster will help promote MyndSystem™ as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives®, Inc. (OTCID:BDPT) announced today that UFC Hall of Famer and former UFC middleweight champion Michael Bisping has joined MyndSystem™ as a paid brand ambassador. The partnership will focus on promoting MyndMed™ and MyndRenew™, the products at the core of the MyndSystem™ platform.
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced a shareholder update on its current capital restructuring, adjustments in executive equity, and long-term operational strategies.
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks. LAS VEGAS, NV / ACCESS Newswire / August 12, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced the official commercial launch and pre-order availability of XcellaraHeart™, a breakthrough, pharmaceutical-grade daily cardiovascular supplement.
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new Xcellara™ cellular wellness line, will take place later this week. Customers and distributors will soon be able to place orders directly through products.xcellara.com.
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, announced it has successfully retired its largest convertible commercial investor.
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront operations and direct-to-consumer (DTC) marketing footprint for its flagship cognitive performance line, MyndSystem™. The MyndSystem™ is a WADA-compliant, stimulant-free cognitive enhancement suite designed to support 24-hour brain performance.
BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches
LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.
